The AACC DRUG MONITORING DATA POCKET GUIDE is an up-to-date, easy-to-use source of information on the most commonly measured therapeutic drugs in today's clinical laboratory. It provides a quick reference to drug pharmacokinetics, analysis & sample handling. References are provided for those needing more detail. The guide will be very useful for clinical scientists involved in therapeutic drug monitoring & as an education aid. 1994, 4 1/2 x 6 Softcover, ISBN 0-915274-70-1, $15, Order #625.

Therapeutic Drug Monitoring Data: A Concise Guide, Fourth Edition serves as a ready resource of information on commonly monitored drugs that will help readers make decisions relating to the monitoring and interpretation of results. It is an easy-to-read source of information on intended use, pharmacokinetics, therapeutic range, and toxic concentrations, as well as bioavailability, disposition, metabolism and the excretion of commonly monitored therapeutic drugs. This fully updated fourth edition includes sections on new anticonvulsants, anti-depressant and anti-HIV drugs, new drugs for advanced cancer treatment, and thoroughly updated chapters that address new pitfalls and problems in the lab. - Serves as a ready resource of information for commonly monitored drugs - Presents a useful, quick guide for those making decisions related to monitoring and interpretation of results - Provides concise, easily digestible content for clinical laboratory scientists, toxicologists and clinicians

Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety. - Includes both the technical and clinical issues associated with therapeutic drug monitoring - Discusses the utility of therapeutic drug monitoring of newer drugs such as antiretroviral agents, anticonvulsants, antidepressants etc. - Provides up-to-date information on issues in pharmacogenomics and personalized medicine with emphasis on therapy with warfarin, certain anticancer drugs and antidepressants - Covers important content on the limitations of commercially available immunoassays (chemical tests) for therapeutic drug monitoring and additional analytical techniques

Drug Monitoring and Clinical Chemistry, the 5th volume in the Handbook of Analytical Separations series, gives an overview about methods to analyse drugs in biological fluids. The most widely used methods to analyse drugs in biological fluids. i.e. chromatographic methods, CE and immunoassays are described in detail. For important drugs, an overview about the methods available and a comparison of the techniques should be given to enable the reader to choose the right method depending on laboratory equipment, staff, the aim of the investigation etc. Other general aspects important for conducting therapeutic drug monitoring or pharmacokinetics studies are also covered, i.e. sample preparation, validation of the analytical methods and pharmacokinetic methods for interpreting the data. Areas where therapeutic drug monitoring is used frequently such as antibiotics, immunosuppressant drugs, antipsychotic and anticancer drugs will be discussed in detail. In addition, the important field of phenotyping and genotyping for therapy optimisation with special focus on real-life applications is also covered. The book contains important information for analyst working on drug analysis in clinical chemistry, hospital pharmacists involved in therapeutic drug monitoring, other pharmacists, chemists or physicians working on pharmacokinetic studies in industry or academia. In contrast to other books in this field, this book provides up-to-date information regarding both methodology and clinical applications. For the applications, only fields are described where therapeutic drug monitoring is used in clinical routine and provides benefit to the patients. - Overview of all important field where therapeutic drug monitoring is applied - All relevant analytical and computational methods are discussed - Written by experts with a lot of practical experience in the field

Methods of Therapeutic Drug Monitoring Including Pharmacogenetics, Second Edition, Volume Seven in the Handbook of Analytical Separations series, covers all aspects of drug monitoring, including laboratory work, pharmacokinetic analysis and clinical aspects, thus enabling readers from different fields to understand the whole process of therapeutic drug monitoring and how to avoid common pitfalls. The book contains analytical techniques for the quantification of drugs, along with pharmacogenetic and pharmacogenomic methods. Also included are updates on sample preparation, including dried blood spot technology and microextraction methods. In addition, the book includes new drugs, such as tyrosine kinase inhibitors and the monitoring of immunosuppressant drugs. - Presents a unique, interdisciplinary approach that appeals to a wide range of users - Written by authors from international labs, providing a global perspective that can be applied in various regulatory environments - Features additional therapeutic drugs to reflect the rising number of immunocompromised patients - Includes a new mass spectroscopic methods chapter to capture the frequent use in TDM and the improved availability of LC-MS across laboratories

Quick, Accurate Diagnosis from Lab Results in the Palm of Your Hand! Healthcare professionals will value the Lab Reference Pocket Guide – a convenient, easy-to-use pocket guide to laboratory testing. Featuring several hundred lab tests, each test has a brief description, norms for adults and children, and panic values. The primary purpose of the guide is to quickly identify what disease or drug has caused the test to be high or low, and then to determine a working diagnosis for the client. An alphabetized list of drugs allows providers to easily determine what lab tests to review. This is the definitive, evidence-based guide to lab testing!!

Praise for the first edition: "Given the author’s years of experience as a statistician and as a founder of the first DMC in pharmaceutical industry trials, I highly recommend this book—not only for experts because of its cogent and organized presentation, but more importantly for young investigators who are seeking information about the logistical and philosophical aspects of a DMC." -S. T. Ounpraseuth, The American Statistician In the first edition of this well-regarded book, the author provided a groundbreaking and definitive guide to best practices in pharmaceutical industry data monitoring committees (DMCs). Maintaining all the material from the first edition and adding substantial new material, Data and Safety Monitoring Committees in Clinical Trials, Second Edition is ideal for training professionals to serve on their first DMC as well as for experienced clinical and biostatistical DMC members, sponsor and regulatory agency staff. The second edition guides the reader through newly emerging DMC responsibilities brought about by regulations emphasizing risk vs benefit and the emergence of risk-based monitoring. It also provides the reader with many new statistical methods, clinical trial designs and clinical terminology that have emerged since the first edition. The references have been updated and the very popular end-of-chapter Q&A section has been supplemented with many new experiences since the first edition. New to the Second Edition: Presents statistical methods, tables, listings and graphs appropriate for safety review, efficacy analysis and risk vs benefit analysis, SPERT and PRISMA initiatives. Newly added interim analysis for efficacy and futility section. DMC responsibilities in SUSARs (Serious Unexpected Serious Adverse Reactions), basket trials, umbrella trials, dynamic treatment strategies /SMART trials, pragmatic trials, biosimilar trials, companion diagnostics, etc. DMC responsibilities for data quality and fraud detection (Fraud Recovery Plan) Use of patient reported outcomes of safety Use of meta analysis and data outside the trial New ideas for training and compensation of DMC members Jay Herson is Senior Associate, Biostatistics, Johns Hopkins Bloomberg School of Public Health where he teaches courses on clinical trials and drug development based on his many years experience in clinical trials in academia and the pharmaceutical industry.

Providing portable and practical information for evaluating intrapartum and antepartum fetal status specifically for use in the clinical environment, this handy guide explains the care and management of the patient in the labor and delivery suite, the fetal intensive care unit, and the antepartum inpatient unit or ambulatory care setting. It also provides up-to-date content on all aspects of electronic fetal monitoring, from operating equipment to interpreting data.